Assignee
XENON PHARMACEUTICALS INC
CA·62 granted patents·43 pending applications·500 citations·filing 2001–2025
Top patents by PatentIndex Score
105 records- 0196US10815229B1Benzenesulfonamide compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2020·Granted Oct 27, 2020·4 cites·29 claims
- 0295US11299490B2Benzenesulfonamide compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2020·Granted Apr 12, 2022·3 cites·24 claims
- 0395US7700641B2Spiro-oxindole compounds and their uses as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2006·Granted Apr 20, 2010·39 cites·41 claims
- 0495US7511018B2Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereofXENON PHARMACEUTICALS INC·Filed 2005·Granted Mar 31, 2009·27 cites·18 claims
- 0594US8030488B2Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2008·Granted Oct 4, 2011·34 cites·28 claims
- 0693US7767677B2Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitorsXENON PHARMACEUTICALS INC·Filed 2005·Granted Aug 3, 2010·34 cites·10 claims
- 0792US10246453B2Benzenesulfonamide compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·10 cites·68 claims
- 0892US7935721B2Spiro-oxindole compounds and their uses as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2009·Granted May 3, 2011·18 cites·15 claims
- 0992US7799798B2Spiroheterocyclic compounds and their uses as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2006·Granted Sep 21, 2010·26 cites·9 claims
- 1092US7592343B2Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitorsXENON PHARMACEUTICALS INC·Filed 2005·Granted Sep 22, 2009·22 cites·6 claims
- 1192US7335658B2Pyridazine derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2004·Granted Feb 26, 2008·59 cites·95 claims
- 1291US11091441B2Solid state crystalline forms of a selective potassium channel modulatorXENON PHARMACEUTICALS INC·Filed 2020·Granted Aug 17, 2021·4 cites·62 claims
- 1391US10662184B2Benzenesulfonamide compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2019·Granted May 26, 2020·4 cites·3 claims
- 1491US7547698B2Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)XENON PHARMACEUTICALS INC·Filed 2005·Granted Jun 16, 2009·18 cites·9 claims
- 1590US11174268B2Benzenesulfonamide compouds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2020·Granted Nov 16, 2021·2 cites·25 claims
- 1690US7390813B1Pyridylpiperazines and aminonicotinamides and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2002·Granted Jun 24, 2008·35 cites·8 claims
- 1789US10745392B2Benzenesulfonamide compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2019·Granted Aug 18, 2020·4 cites·47 claims
- 1888US9481677B2Biaryl ether sulfonamides and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2012·Granted Nov 1, 2016·17 cites·17 claims
- 1988US7777036B2Heterocyclic derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2005·Granted Aug 17, 2010·13 cites·9 claims
- 2087US11957675B2Methods and uses for treating anhedoniaXENON PHARMACEUTICALS INC·Filed 2022·Granted Apr 16, 2024·1 cites·36 claims
- 2187US11135214B2Methods for enhancing the bio availability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICALS INC·Filed 2019·Granted Oct 5, 2021·3 cites·26 claims
- 2287US9630929B2Benzenesulfonamide compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2012·Granted Apr 25, 2017·11 cites·29 claims
- 2386US7893206B2Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereofXENON PHARMACEUTICALS INC·Filed 2009·Granted Feb 22, 2011·5 cites·17 claims
- 2486US7514436B2Pyridazine derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2004·Granted Apr 7, 2009·22 cites·30 claims
- 2586US7456180B2Piperazine derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2004·Granted Nov 25, 2008·24 cites·25 claims
- 2686US2024316033A1Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2785US9480677B2Enantiomers of spiro-oxindole compounds and their uses as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2014·Granted Nov 1, 2016·5 cites·1 claims
- 2885US7919484B2Combination therapyXENON PHARMACEUTICALS INC·Filed 2006·Granted Apr 5, 2011·10 cites·18 claims
- 2983US11325902B2Benzenesulfonamide compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2020·Granted May 10, 2022·1 cites·33 claims
- 3082US10981905B2Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2019·Granted Apr 20, 2021·1 cites·54 claims
- 3182US9695185B2Synthetic methods for spiro-oxindole compoundsXENON PHARMACEUTICALS INC·Filed 2016·Granted Jul 4, 2017·3 cites·1 claims
- 3282US9487535B2Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2013·Granted Nov 8, 2016·5 cites·26 claims
- 3382US8916580B2Spiro-oxindole compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2013·Granted Dec 23, 2014·4 cites·8 claims
- 3482US2025221980A1Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3580US12171759B1Methods and uses for treating anhedoniaXENON PHARMACEUTICALS INC·Filed 2024·Granted Dec 24, 2024·0 cites·27 claims
- 3679US12319657B1Solid state crystalline forms of a selective potassium channel modulatorXENON PHARMACEUTICALS INC·Filed 2025·Granted Jun 3, 2025·0 cites·30 claims
- 3779US10513526B2Solid state forms of spiro-oxindole compoundsXENON PHARMACEUTICALS INC·Filed 2018·Granted Dec 24, 2019·2 cites·11 claims
- 3879US9260446B2Synthetic methods for spiro-oxindole compoundsXENON PHARMACEUTICALS INC·Filed 2014·Granted Feb 16, 2016·4 cites·5 claims
- 3978US10118932B2Solid state forms of spiro-oxindole compoundsXENON PHARMACEUTICALS INC·Filed 2017·Granted Nov 6, 2018·2 cites·11 claims
- 4078US8026360B2Substituted pyridazines as stearoyl-CoA desaturase inhibitorsXENON PHARMACEUTICALS INC·Filed 2009·Granted Sep 27, 2011·3 cites·5 claims
- 4177US2022062266A1Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4276US2024408075A1Conjoint therapy for treating seizure disordersXENON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4375US10752623B2Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitorsXENON PHARMACEUTICALS INC·Filed 2019·Granted Aug 25, 2020·1 cites·38 claims
- 4475US7754711B2Pyridazine derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2005·Granted Jul 13, 2010·2 cites·6 claims
- 4575US2025275957A1Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel openerXENON PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 4675US2024342156A1Methods for treating painXENON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4775US2025186426A1Methods and uses for treating anhedoniaXENON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4875US2024279182A1Solid state crystalline forms of a selective potassium channel modulatorXENON PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4974US7816075B2Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2005·Granted Oct 19, 2010·1 cites·7 claims
- 5074US7785886B2Methods and reagents for modulating cholesterol levelsXENON PHARMACEUTICALS INC·Filed 2004·Granted Aug 31, 2010·5 cites·5 claims
Showing the top 50 of 105 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →